newsfilter
← Latest News
GlobeNewswire·

Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis Completed IND-enabling studies for OD-002, a first-in-class oral SLC15A4 inhibitor